Program
adecatumumab
Also written as “MT-201”, “Adecatumumab” and “Adecatumumab and FOLFOX”.
Its studies are mostly in Inflammatory Bowel Diseases · Colorectal Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mirador Therapeutics | 32 open or running | phase 2since Jul 15, 2025 | Jul 15, 2025 | Apr 30, 2027phase 2 · NCT07113522 |
| Amgen | 10 open or running | phase 2since Mar 20, 2009 | Mar 20, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 20, 2009First study: phase 2 study in Colorectal NeoplasmsNew to AmgenAmgen · NCT00866944 · 35 enrolled · France, Germany
- Jul 15, 2025Mirador Therapeutics's first study: phase 2 study in Inflammatory Bowel DiseasesNew to Mirador TherapeuticsMirador Therapeutics · NCT07113522 · 140 planned · United States, Canada, Georgia and more
- Oct 17, 2025Phase 1 study in Healthy VolunteerMirador Therapeutics · NCT07219368 · 56 enrolled · United States
- Aug 17, 2026Phase 1 study in Healthy VolunteerMirador Therapeutics · NCT07776782 · 25 planned · United States
Ahead
- Nov 12, 2026Primary completion: phase 1 study in Healthy VolunteerMirador Therapeutics · NCT07776782
- Apr 30, 2027Primary completion: phase 2 study in Inflammatory Bowel DiseasesMirador Therapeutics · NCT07113522
TargetBeta
“Epithelial cell adhesion molecule inhibitor”ChEMBL 37, by rule
Other programs on EPCAM
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-EpCAM/Anti-4-1BB Bispecific Antibody BNT314rule | BioNTech | phase 2 | 2 |
| LTZ-232rule | ltz-therapeutics-inc | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07776782Healthy Volunteer · United States | 1 | Recruiting | Mirador Therapeutics | Nov 12, 2026 | 25 |
| NCT07219368Healthy Volunteer · United States | 1 | Completed | Mirador Therapeutics | Oct 20, 2026 | 56 |
| NCT07113522Inflammatory Bowel Diseases · United States, Canada, Georgia and more | 2 | Recruiting | Mirador Therapeutics | Apr 30, 2027 | 140 |
| NCT00866944Colorectal Neoplasms · France, Germany | 2 | Completed | Amgen | Jul 2011 | 35 |
How it is read
Names in the registry
- “MT-201”, 3 entries
- “Adecatumumab”, 1 entry
- “Adecatumumab and FOLFOX”, 1 entry
Conditions, from the studies’ own filings
- Inflammatory Bowel Diseases, 1 study
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.